Actualizado
CADILA Healthcare became rocket after USFDA approval
#CADILAHC has received tentative approval from the USFDA to market Carbidopa and Levodopa extended release capsules and stock became rocket and break the level 400 that was strong resistance. Currently stock closed above 400 level.
Showing Bullish result in Technical Parameter:
CCI in overbought zone
RSI crossed above 70
MFI crossed above 80
Stoch in overbought zone
Making higher high since 3 days
DI+ treading above DI-
New Long position
----------------------------------------------------------
Resistance : 410 & 420 & 433
Breakout : 406
LTP : 404.90
Breakdown : 399.75
Support : 390 & 385 & 374
----------------------------------------------------------
Positive & Negative Point:
1) Very Bullish in Daily/Weekly/Monthly chart.
----------------------------------------------------------
(Disclaimer: This is only for educational purpose and paper treading. Learn and take advice from you financial advisor)
Showing Bullish result in Technical Parameter:
CCI in overbought zone
RSI crossed above 70
MFI crossed above 80
Stoch in overbought zone
Making higher high since 3 days
DI+ treading above DI-
New Long position
----------------------------------------------------------
Resistance : 410 & 420 & 433
Breakout : 406
LTP : 404.90
Breakdown : 399.75
Support : 390 & 385 & 374
----------------------------------------------------------
Positive & Negative Point:
1) Very Bullish in Daily/Weekly/Monthly chart.
----------------------------------------------------------
(Disclaimer: This is only for educational purpose and paper treading. Learn and take advice from you financial advisor)
Nota
Hit the target 410 and pull back from level 392Operación cerrada: objetivo alcanzado
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.